Table 2.
Participant Characteristics at Baseline
| All (n=188) | Eventual Abstainers (n=94) | Continuing Smokers (n=94) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable | Mean or N |
SD or % |
Range | Mean or N |
SD or % |
Range | Mean or N |
SD or % |
Range |
| Age (years) | 50.3 | 11.4 | 24 - 79 | 50.0 | 11.6 | 24 - 79 | 50.5 | 11.1 | 25 - 74 |
| Sex (% female) | 107 | 56.9% | - | 54 | 57.4% | - | 53 | 56.4% | - |
| Race (%) | |||||||||
| White | 162 | 86.2% | - | 81 | 86.2% | 81 | 86.2% | - | |
| Non-White | 26 | 13.8% | - | 13 | 13.8% | - | 13 | 13.8% | |
| Body mass index (kg/m2) | 28.2 | 5.3 | 15.9 - 42.0 | 28.3 | 5.4 | 16.1 - 41.7 | 28.1 | 5.2 | 15.9 - 42.0 |
| Markers of smoking burden | |||||||||
| Cigarettes per day | 16.8 | 7.6 | 3 - 40 | 16.9 | 7.8 | 5 - 40 | 16.8 | 7.4 | 3 - 40 |
| Pack-years | 26.4 | 17.9 | 3.3 - 106 | 26.2 | 18.0 | 3.8 - 86 | 26.6 | 17.9 | 3.3 - 106 |
| FTCD | 4.6 | 2.2 | 0 - 9 | 4.2 | 2.2 | 0 - 9 | 4.9 | 2.1 | 0 - 9 |
| Carbon monoxide (ppm) | 8.8 | 6.9 | 2 - 72 | 8.4 | 5.6 | 2 - 29 | 9.2 | 8.0 | 2 - 72 |
| C-reactive protein (mg/L) | 4.1 | 6.2 | 0.2 - 64.1 | 4.4 | 7.3 | 0.2 - 64.1 | 3.8 | 4.9 | 0.2 - 42.5 |
| White blood cell count (K/μL) | 7.7 | 2.1 | 3.4 - 18.1 | 7.6 | 1.9 | 3.4 −12.8 | 7.8 | 2.3 | 3.7 - 18.1 |
| Systolic blood pressure (mm/Hg) | 120.4 | 13.8 | 88 - 158 | 121.1 | 14.1 | 88 −158 | 119.7 | 13.5 | 88 - 158 |
| Diastolic blood pressure (mm/Hg) | 74.3 | 10.3 | 50 - 98 | 74.7 | 11.1 | 50 - 98 | 73.9 | 9.6 | 50 - 94 |
| HOMA-IR | 2.1 | 2.1 | 0.18 - 22.0 | 2.1 | 2.7 | 0.18-22.0 | 2.1 | 1.4 | 0.2 - 7.6 |
| Lipids | |||||||||
| Total cholesterol (mg/dL) | 193.1 | 37.3 | 84 - 296 | 196.0 | 37.0 | 123 - 296 | 190.3 | 37.6 | 84 - 199 |
| Low-density lipoprotein cholesterol (mg/dL) | 114.8 | 30.0 | 39 - 195 | 117.3 | 28.8 | 54 - 195 | 112.3 | 31.0 | 39 - 192 |
| High-density lipoprotein cholesterol (mg/dL) |
50.7 | 19.2 | 19 - 149 | 50.6 | 19.9 | 22 - 149 | 50.8 | 18.6 | 19 - 112 |
| Triglycerides (mg/dL) | 137.1 | 87.3 | 31- 801 | 138.6 | 103.0 | 31 - 801 | 135.7 | 68.8 | 52 - 371 |
| Non-high-density lipoprotein cholesterol | 142.4 | 37.8 | 51 - 274 | 145.4 | 39.7 | 72 - 274 | 139.4 | 35.7 | 51 - 242 |
| Lipid-lowering medication (yes) | 37 | 19.7% | 16 | 17% | 21 | 22.3% | |||
| Diabetes medication (yes) | 15 | 8.0% | 3 | 3.2% | 12 | 12.8%* | |||
| Anti-hypertension medication (yes) | 54 | 28.7% | 21 | 22.3% | 33 | 35.1% | |||
| GSM (units) | 57.3 | 13.9 | 21.9 - 105.7 | 58.5 | 14.7 | 21.9 - 105.7 | 56.0 | 13.0 | 32.4 - 97.4 |
| Entropy (units) | 4.2 | 0.1 | 3.9 - 4.5 | 4.2 | 0.1 | 3.9 - 4.5 | 4.2 | 0.1 | 3.9 - 4.5 |
| GLDS-CON (units) | 66.4 | 20.3 | 25.4 - 167.1 | 65.1 | 18.6 | 25.4 - 130.6 | 67.8 | 22.0 | 34.1 - 167.1 |
| SGLDM-ASM (units) (x1000) | 2.2 | 0.8 | 1.2 - 6.5 | 2.3 | 0.6 | 1.2 - 3.9 | 2.4 | 0.9 | 1.2 - 6.5 |
FTCD, Fagerström Test for Cigarette Dependence, scoring scale of 0–10; HOMA-IR, homeostasis model of insulin resistance; GLDS-CON, gray level difference statistics – contrast; GSM, grayscale median; SGLDM-ASM, spatial gray level dependence matrices – angular second moment.
*
indicates significance of p<0.05